News
May 12, 2022
TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting
May 9, 2022
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
May 2, 2022
TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting
April 11, 2022
TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance
March 9, 2022
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
March 2, 2022
TScan Therapeutics to Participate in Upcoming Investor Conferences
February 10, 2022
TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference
January 24, 2022
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies
January 10, 2022
TScan Outlines 2022 Priorities as Programs Enter Clinic
December 13, 2021